Your browser doesn't support javascript.
SARS-CoV-2 Vaccines: Status Report.
Amanat, Fatima; Krammer, Florian.
  • Amanat F; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: florian.krammer@mssm.edu.
Immunity ; 52(4): 583-589, 2020 04 14.
Article in English | MEDLINE | ID: covidwho-20439
ABSTRACT
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus / Drug Development Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Country/Region as subject: Asia Language: English Journal: Immunity Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: J.immuni.2020.03.007

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Pandemics / Betacoronavirus / Drug Development Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Country/Region as subject: Asia Language: English Journal: Immunity Journal subject: Allergy and Immunology Year: 2020 Document Type: Article Affiliation country: J.immuni.2020.03.007